hematologic disease: A disease involving the hematopoietic system.
Other specified diseases with participation of lymphoreticular and reticulohistiocytic tissue
DOID EFO Endpoint Browser PheWeb
D3_OTHDISLYMPHORETANDRETICULOHIST
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
148 |
4. Check minimum number of eventsNone |
148 |
5. Include endpoints |
148 |
6. Filter based on genotype QC (FinnGen only) |
126 |
Control definitions (FinnGen only)
- Control exclude
- D3_BLOODOTHER
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D70-D77
- Name in latin
- Aliqui morbi textus lymphoreticularis et systematis reticulohistiocytici
Similar endpoints
↥List of similar endpoints to
Other specified diseases with participation of lymphoreticular and reticulohistiocytic tissue
based on the number of shared cases.
Similar with more cases:
- Other diseases of blood and blood-forming organs, wide
- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 896 | 420 | 473 |
| Only index persons | 719 | 332 | 387 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 34.32 | 35.37 | 33.34 |
| Only index persons | 41.02 | 42.89 | 39.42 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 126 | 60 | 66 |
| Unadjusted period prevalence (%) | 0.03 | 0.02 | 0.03 |
| Median age at first event (years) | 53.65 | 52.75 | 54.48 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 130
- Matched controls
- 1300
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D76.1
ICD-10 Finland
Haemophagocytic lymphohistiocytosis
+∞
57.7
51
*
D76.3
ICD-10 Finland
Other histiocytosis syndromes
+∞
55.2
49
*
D76.00
ICD-10 Finland
Eosinophilic granuloma
+∞
36.1
33
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
9.2
29.6
45
71
D76.01
ICD-10 Finland
Histiocytosis X (chronic)
+∞
28.1
26
*
XW000
NOMESCO Finland
Bone marrow biopsy
35.0
28.1
36
14
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
25.5
23.7
33
17
R50.9
ICD-10 Finland
Fever, unspecified
5.8
20.1
51
131
JN4AD
NOMESCO Finland
Body CT examination
6.6
19.0
37
74
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
8.5
18.1
26
37
GD1AD
NOMESCO Finland
Thorax CT examination
8.9
18.1
25
34
UGC12
NOMESCO Finland
Flexible bronchoscopy
8.3
17.7
26
38
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
5.1
17.6
51
145
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
6.5
17.1
33
65
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
6.4
16.8
33
66
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
5.4
16.6
42
106
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
7.7
16.0
25
39
JN4BD
NOMESCO Finland
Extensive body CT
6.1
15.7
32
66
H02AB09
ATC
hydrocortisone; systemic
18.1
15.6
24
16
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
64.6
15.2
17
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
7.1
13.9
23
38
H02AB06
ATC
prednisolone; systemic
4.0
13.1
87
434
WW500
NOMESCO Finland
Blood transfusion
12.4
12.9
23
22
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
6.4
12.6
23
42
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
12.3
11.8
21
20
D76.0
ICD-10 Finland
Langerhans' cell histiocytosis, not elsewhere classified
+∞
11.6
11
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.6
11.1
84
440
A41.9
ICD-10 Finland
Sepsis, unspecified
11.6
11.0
20
20
N17.9
ICD-10 Finland
Acute renal failure, unspecified
11.6
11.0
20
20
D76.2
ICD-10 Finland
Haemophagocytic syndrome, infection-associated
+∞
10.6
10
*
H02AB02
ATC
dexamethasone; systemic
4.4
10.4
31
87
D69.6
ICD-10 Finland
Thrombocytopenia, unspecified
22.2
10.0
14
7
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
4.9
9.9
24
57
JN6AD
NOMESCO Finland
CT of torso and neck
59.6
9.8
11
*
A04AA01
ATC
ondansetron; systemic, rectal
5.1
9.8
23
53
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
4.3
9.6
29
82
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.8
9.4
35
115
TAB00
NOMESCO Finland
Lumbar puncture
5.4
8.9
19
40
ZX120
NOMESCO Finland
Intravenous
4.5
8.9
24
62
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
14.1
8.6
14
11
D64.9
ICD-10 Finland
Anaemia, unspecified
4.2
8.5
25
69
EN1AD
NOMESCO Finland
CT examination of mouth and soft tissues of neck
+∞
8.4
8
*
D70.82
ICD-10 Finland
Drug-induced neutropenia
+∞
8.4
8
*
R59.0
ICD-10 Finland
Localized enlarged lymph nodes
9.3
7.6
15
18
PJ2AE
NOMESCO Finland
Lymphnode ultrasound examination
84.7
7.5
8
*
JN6BD
NOMESCO Finland
Extensive CT of torso and neck
84.7
7.5
8
*
NK6CT
NOMESCO Finland
Bone biopsy with CT guidance
84.7
7.5
8
*
WX892
NOMESCO Finland
Monitored bed care
4.6
7.4
19
47
TPH04
NOMESCO Finland
Cathetrisation of vein
3.1
7.4
40
165
EP1AE
NOMESCO Finland
Neck ultrasound examination
6.2
7.3
19
35
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
9.1
7.0
14
17
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.7
7.0
54
269
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
3.8
6.9
23
69
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
13.2
6.7
11
9
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
8.1
6.6
14
19
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
6.1
6.6
17
31
TPX10
NOMESCO Finland
Implantation of vascular injection port
7.2
6.6
15
23
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
4.3
6.5
18
47
M04AA01
ATC
allopurinol; systemic
3.3
6.4
27
95
102
Kela drug reimbursment
Diabetes insipidus
+∞
6.3
6
*
WX002
NOMESCO Finland
Sedation and analgesia
3.0
6.2
33
133
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
44
7
93.70
41.25
8.6
2.1
4273.80
613.71
u/ml
—
44
7
44
49
13.06
38.33
3.2
1.8
1.55
1.68
g/l
0.27
33
43
33
24
18.09
37.04
2.1
4.8
1.47
2.95
ratio
0.54
17
11
28
28
12.47
25.65
1.6
2.2
—
—
—
0
0
32
40
10.29
25.05
3.2
2.6
—
—
—
0
0
28
32
10.88
23.32
3.2
1.7
—
—
—
0
0
29
35
10.38
23.22
3.9
1.7
—
—
—
0
0
29
11
33.44
22.53
3.8
4.6
—
—
—
0
0
33
21
20.61
22.06
2.2
3.2
—
—
—
0
0
28
37
9.37
20.82
1.7
1.4
—
—
—
0
0
59
170
5.52
20.48
13.2
8.0
1.15
1.15
mmol/l
0.03
59
159
23
8
34.48
18.14
2.1
1.4
—
—
—
0
0
16
0
+∞
17.04
2.2
0.0
—
—
—
0
0
24
35
8.18
16.31
2.0
1.6
—
—
—
0
0
29
53
6.76
16.08
9.1
3.2
90.03
93.96
%
0.28
29
53
27
50
6.55
14.72
3.1
1.5
11.33
4.87
iu/ml
—
6
11
26
25
12.70
14.56
1.3
1.8
—
—
—
0
0
59
214
4.22
14.50
12.7
5.5
0.80
0.81
mmol/l
0.32
59
203
25
24
12.61
14.00
3.9
1.7
—
—
—
0
0
26
28
11.32
13.78
1.7
1.5
—
—
—
0
0
25
25
12.10
13.73
1.5
1.9
99.40
113.54
au/ml
—
5
10
102
568
4.69
13.14
21.4
8.7
1.21
1.21
mmol/l
0.27
87
501
30
71
5.19
12.52
3.6
1.4
—
—
—
0
0
23
24
11.39
12.36
1.7
1.3
—
—
—
0
0
20
16
14.53
12.11
2.2
1.7
—
—
—
0
0
51
187
3.84
11.99
4.4
1.7
—
—
—
0
0
111
688
5.20
11.64
37.4
10.5
4.26
3.96
e9/l
0.27
103
591
23
27
10.10
11.63
1.8
1.6
—
—
—
0
0
23
27
10.10
11.63
1.6
2.2
272.15
126.42
u/ml
1.24
13
12
39
122
4.14
11.42
3.4
2.4
302.33
361.83
nmol/l
1.38
39
112
23
28
9.73
11.41
1.7
1.4
—
—
—
0
0
32
87
4.55
11.25
1.4
1.4
72.86
322.43
u/ml
0.80
26
80
18
17
12.08
10.16
1.5
1.2
—
—
—
0
0
17
16
12.03
9.62
4.8
1.6
—
—
—
0
0
17
18
10.68
9.10
2.4
1.7
—
—
—
0
0
14
11
14.08
8.60
4.5
1.4
32.14
31.64
pg
0.13
14
11
15
14
11.94
8.55
5.3
1.7
—
—
—
0
0
19
42
5.13
8.43
11.1
2.8
201.84
207.00
%
0.08
19
42
19
29
7.48
8.26
2.1
1.2
—
—
—
0
0
13
10
14.27
8.07
1.8
1.2
—
—
—
0
0
12
9
14.52
7.55
1.9
1.2
—
—
—
0
0
36
140
3.17
7.32
3.6
1.6
—
—
—
0
0
10
5
21.48
7.25
1.1
1.0
—
—
—
0
0
35
136
3.15
7.11
3.2
1.6
—
—
—
0
0
27
90
3.52
6.99
3.3
5.4
47.81
78.87
ng/l
2.51
22
79
13
14
10.17
6.97
1.2
1.0
—
—
—
0
0
16
26
6.86
6.72
1.4
1.2
—
—
—
0
0
11
9
13.21
6.71
1.2
1.0
—
—
—
0
0
12
12
10.88
6.69
1.9
1.5
—
—
—
0
0
12
12
10.88
6.69
1.8
1.8
—
—
—
0
0
17
31
6.14
6.57
1.5
2.5
2.45
22.83
e6/l
0.47
11
24
82
513
2.62
6.50
7.4
2.9
—
—
estimate
—
0
0
10
8
13.40
6.19
1.8
1.0
—
—
—
0
0
58
316
2.51
6.06
4.4
4.0
2453.94
1088.36
ng/l
0.56
53
269
12
15
8.68
5.98
1.7
1.9
—
—
—
0
0
10
9
11.91
5.90
1.8
1.1
—
—
—
0
0
26
94
3.21
5.89
5.8
5.1
1.36
1.42
mmol/l
0.02
20
68
32
132
2.89
5.78
17.2
5.8
1.29
1.60
mmol/l
0.24
25
108
14
26
5.90
5.40
5.1
4.0
4.75
4.84
kpa
0.17
14
26
31
132
2.77
5.25
6.3
13.8
0.22
0.81
mmol/l
0.42
24
114
5
0
+∞
5.24
1.6
0.0
—
—
—
0
0
9
10
9.56
4.86
5.0
1.8
—
—
—
0
0
9
10
9.56
4.86
5.0
1.8
—
—
—
0
0
9
10
9.56
4.86
5.0
1.8
—
—
—
0
0
8
7
12.07
4.85
3.5
2.4
—
—
—
0
0
7
5
14.68
4.63
1.3
1.8
—
—
—
0
0
7
6
12.23
4.32
1.9
1.2
—
—
—
0
0
29
132
2.54
4.26
6.6
13.7
4.59
5.15
kpa
2.80
29
125
29
132
2.54
4.26
6.6
13.7
11.17
12.15
kpa
0.68
29
126
33
163
2.37
4.07
18.1
7.9
104.45
104.06
mmol/l
0.21
33
163
7
7
10.47
4.06
1.4
1.0
—
—
—
0
0
16
54
3.24
4.01
2.1
2.3
17.03
22.54
iu/l
—
9
45
24
105
2.58
3.80
19.4
10.6
23.95
24.51
mmol/l
0.38
24
105
6
5
12.48
3.80
5.8
2.0
—
—
—
0
0
6
5
12.48
3.80
6.0
2.0
—
—
—
0
0
6
5
12.48
3.80
5.8
2.0
—
—
—
0
0
6
5
12.48
3.80
6.0
2.0
—
—
—
0
0
6
5
12.48
3.80
6.0
2.0
—
—
—
0
0
6
5
12.48
3.80
1.8
2.2
0.67
0.59
mmol/l
—
6
5
6
5
12.48
3.80
5.8
2.0
—
—
—
0
0
6
5
12.48
3.80
6.0
2.0
—
—
—
0
0
47
276
2.10
3.79
8.0
2.4
—
—
—
0
0
19
74
2.84
3.75
8.1
14.4
94.95
93.47
%
0.82
19
74
9
16
5.95
3.73
2.0
1.1
—
—
—
0
0
7
9
8.14
3.60
1.1
1.7
—
—
—
0
0
9
17
5.60
3.58
1.6
1.1
1.80
1.40
g/l
—
9
17
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
6
6
10.40
3.53
1.5
1.2
—
—
—
0
0
13
37
3.79
3.52
1.8
1.3
—
—
—
0
0
6
7
8.91
3.30
1.8
3.6
107.17
83.86
%
—
6
7
53
340
1.94
3.26
5.9
3.7
0.41
0.31
e6/l
0.15
46
253
13
40
3.50
3.25
4.8
4.2
22.85
24.54
mmol/l
1.24
13
40
11
31
3.78
3.07
2.6
1.5
—
—
—
0
0
12
38
3.37
2.94
5.4
1.9
—
—
—
0
0
9
22
4.31
2.94
1.3
1.3
—
—
—
0
0
60
415
1.83
2.84
5.5
3.9
30.97
26.51
ng/l
0.35
47
293
7
14
5.22
2.76
1.0
1.1
—
—
—
0
0
7
14
5.22
2.76
1.0
1.1
—
—
—
0
0
6
10
6.23
2.73
1.0
1.1
—
—
—
0
0
6
10
6.23
2.73
1.0
1.1
—
—
—
0
0
6
10
6.23
2.73
1.0
1.1
—
—
—
0
0
6
10
6.23
2.73
1.0
1.1
—
—
—
0
0
6
11
5.66
2.57
2.7
1.3
—
—
—
0
0
6
11
5.66
2.57
2.7
1.3
—
—
—
0
0
6
11
5.66
2.57
2.7
1.3
—
—
—
0
0
22
111
2.18
2.54
6.9
3.3
—
—
—
0
0
37
228
1.87
2.48
1.5
1.2
37.31
23.34
iu/ml
0.30
13
73
6
12
5.18
2.43
1.0
1.1
—
—
—
0
0
6
12
5.18
2.43
1.5
1.3
—
—
—
0
0
35
214
1.87
2.40
4.1
3.6
35.43
305.31
ng/l
1.24
28
161
14
59
2.54
2.38
3.3
1.6
—
—
—
0
0
6
13
4.78
2.30
1.0
1.1
—
—
—
0
0
48
329
1.73
2.24
6.8
4.0
0.00
0.01
estimate
0.50
24
124
77
600
1.69
2.23
6.0
3.9
0.00
0.00
estimate
-0.00
27
129
5
9
5.72
2.23
5.2
4.8
1.20
0.89
%
—
5
9
18
89
2.19
2.18
24.0
6.8
23.64
23.80
mmol/l
0.12
18
89
77
605
1.67
2.12
6.0
3.9
0.00
0.00
estimate
-0.00
26
131
9
31
3.04
2.12
2.6
1.2
—
—
—
0
0
77
607
1.66
2.08
6.0
3.9
0.00
0.00
estimate
-0.00
26
121
11
44
2.64
2.07
1.7
1.3
—
—
—
0
0
5
11
4.68
1.96
3.0
1.3
—
—
—
0
0
5
11
4.68
1.96
3.0
1.3
—
—
—
0
0
5
11
4.68
1.96
3.0
1.3
—
—
—
0
0
17
86
2.12
1.95
1.5
2.9
57.75
67.70
ml/min/173m2
—
8
37
61
461
1.61
1.90
2.7
2.0
87.14
95.71
pmol/l
0.98
45
245
5
12
4.29
1.84
1.4
1.1
—
—
—
0
0
9
36
2.61
1.78
3.2
1.7
—
—
—
0
0
6
19
3.26
1.68
7.5
7.3
15.50
10.70
pmol/l
—
6
19
14
70
2.12
1.66
3.3
3.0
88.93
126.54
ng/l
0.42
14
63
11
50
2.31
1.62
2.5
1.2
—
—
—
0
0
6
21
2.94
1.52
1.0
1.0
—
—
—
0
0
6
22
2.81
1.45
2.0
1.5
—
—
—
0
0
6
22
2.81
1.45
2.0
1.5
—
—
—
0
0
5
17
3.02
1.37
5.0
3.4
—
—
—
0
0
29
198
1.60
1.32
1.4
1.3
62.93
5.02
u/ml
—
6
69
58
468
1.43
1.19
6.0
3.7
0.00
0.00
estimate
-0.00
25
113
114
1049
1.70
1.18
6.0
4.9
5.87
5.92
mmol/l
0.14
108
972
12
66
1.90
1.13
25.9
2.6
0.63
0.65
%
0.10
12
66
112
1030
1.63
1.11
6.2
5.0
2.22
1.95
mu/l
0.53
112
948
19
124
1.62
1.04
2.4
5.3
23.33
41.86
ug/l
0.20
13
104
27
194
1.49
0.99
5.1
3.6
1.09
1.92
e6/l
0.59
16
104
106
972
1.49
0.96
54.4
19.4
14.60
13.48
%
6.07
106
967
6
31
1.98
0.85
6.3
3.0
105.17
130.71
g/l
—
6
24
12
73
1.71
0.85
6.8
12.9
22.35
24.99
mmol/l
1.20
12
68
92
999
0.73
0.83
54.2
19.2
331.46
333.71
g/l
1.17
92
999
13
83
1.63
0.78
1.8
2.5
5.98
5.56
ug/l
0.07
13
77
44
360
1.34
0.78
6.4
3.1
0.00
0.01
estimate
0.50
26
109
119
1130
1.63
0.77
49.8
18.1
139.13
139.76
mmol/l
2.24
119
1115
15
100
1.57
0.77
1.7
1.6
—
—
—
0
0
119
1131
1.62
0.75
52.9
18.2
3.99
3.98
mmol/l
0.06
119
1111
119
1134
1.58
0.70
55.1
14.8
29.14
24.55
mg/l
0.93
109
901
5
28
1.82
0.67
1.4
1.1
—
—
—
0
0
27
210
1.36
0.66
4.7
3.5
1.23
0.86
e6/l
0.31
16
119
16
113
1.47
0.65
1.9
2.5
35.88
29.24
u/l
0.42
16
95
122
1179
1.56
0.58
38.3
11.4
39.31
27.02
u/l
2.04
122
1153
56
492
1.24
0.55
2.3
1.9
1.88
1.34
mmol/l
3.42
49
416
42
358
1.26
0.53
7.5
4.0
14.27
8.31
mg/mmol
0.43
35
222
6
40
1.52
0.52
2.3
1.9
—
—
—
0
0
25
304
0.78
0.47
3.9
4.3
25.15
23.24
%
0.16
11
128
5
81
0.60
0.47
1.0
1.1
—
—
—
0
0
12
163
0.71
0.47
4.3
2.2
—
—
—
0
0
31
262
1.24
0.42
1.6
1.8
—
—
—
0
0
122
1187
1.45
0.39
57.1
19.1
83.34
76.90
umol/l
0.62
122
1177
13
103
1.29
0.29
13.5
7.9
—
—
—
0
0
12
148
0.79
0.26
4.3
1.9
—
—
—
0
0
15
125
1.23
0.23
1.9
1.4
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
182.08
—
0
11
0
11
0.00
0.21
0.0
1.8
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
101
1038
0.88
0.19
6.6
6.2
39.12
39.30
mmol/mol
0.05
92
978
36
333
1.11
0.17
1.4
1.5
1.88
1.62
u/ml
—
9
80
18
159
1.15
0.16
1.4
2.2
1.62
1.48
%
0.33
13
143
81
782
1.09
0.15
3.8
3.2
—
—
—
0
0
11
125
0.87
0.10
1.4
2.1
3.82
3.48
ratio
—
6
105
5
61
0.81
0.08
1.0
1.2
—
—
—
0
0
123
1236
0.91
0.08
71.4
23.0
123.47
137.13
g/l
10.22
123
1230
123
1235
0.92
0.08
70.7
22.7
90.77
90.40
fl
0.31
123
1229
123
1235
0.92
0.08
73.9
23.4
36.96
40.84
%
8.10
123
1228
111
1100
1.06
0.04
5.8
5.7
2.47
2.68
mmol/l
1.42
105
1028
109
1082
1.05
0.02
5.6
5.0
1.27
1.43
mmol/l
2.83
104
1006
27
263
1.03
0.01
3.9
3.8
1.02
1.02
kg/l
0.28
18
175
12
126
0.95
0.00
4.1
2.4
9.03
15.38
nmol/l
2.43
12
119
109
1086
1.02
0.00
5.7
5.1
4.31
4.57
mmol/l
1.62
104
1020
0
5
0.00
-0.00
0.0
1.2
—
54.50
—
0
5
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.4
—
19.24
—
0
8
0
8
0.00
-0.00
0.0
2.4
—
4.63
—
0
8
0
7
0.00
-0.00
0.0
1.7
—
41.98
—
0
7
0
5
0.00
-0.00
0.0
7.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.4
—
9.76
—
0
8
7
78
0.89
-0.00
1.6
2.4
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint D3_OTHDISLYMPHORETANDRETICULOHIST and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| D3_OTHDISLYMPHORETANDRETICULOHIST | 4.294 [2.6, 7.1] | < 0.001 |
| Birth year | 0.998 [0.99, 1.01] | 0.683 |
During the follow-up period (1.1.1998 — 31.12.2019), 66 out of 345 females with D3_OTHDISLYMPHORETANDRETICULOHIST died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| D3_OTHDISLYMPHORETANDRETICULOHIST | 3.517 [2.18, 5.68] | < 0.001 |
| Birth year | 0.99 [0.98, 1.0] | 0.029 |
During the follow-up period (1.1.1998 — 31.12.2019), 65 out of 367 males with D3_OTHDISLYMPHORETANDRETICULOHIST died.
Mortality risk
Mortality risk for people of age
years, who have D3_OTHDISLYMPHORETANDRETICULOHIST.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.342% | 0.823% |
| 5 | 2.472% | 4.244% |
| 10 | 5.771% | 10.339% |
| 15 | 11.403% | 19.136% |
| 20 | 20.89% | 30.915% |
Relationships between endpoints
↥Index endpoint: D3_OTHDISLYMPHORETANDRETICULOHIST – Other specified diseases with participation of lymphoreticular and reticulohistiocytic tissue
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data